Rosavin (Phenylpropanoid Glycoside · Adaptogenic · Cognitive Performance)

Compound	Rosavin
Chemical class	Phenylpropanoid Glycoside (Cinnamyl-β-D-Glucopyranosyl-β-D-Apiofuranoside)
CAS	84954-92-7
Primary source	Rhodiola rosea (golden root / arctic root)
Key applications	Adaptogenic, cognitive performance, anti-fatigue, anxiolytic
Claim strength	Moderate
Typical form	Rhodiola rosea extract standardised to rosavin (3%) + salidroside (1%)
Buy from Herbuno	Rhodiola Rosea Extract Powder | Golden Root → Rhodiola Root Liquid Extract (Water Soluble) - Rhodiola rosea | Golden Root →

Name origin: From Rosa — reflecting the rose-like fragrance of freshly cut Rhodiola rhizome, attributed to geraniol rather than rosavin itself. Rosavin is a phenylpropanoid glycoside unique to Rhodiola rosea — a cinnamyl alcohol esterified with a disaccharide (glucose + apiose). Its presence (alongside rosarin and rosin) is chemically diagnostic for R. rosea versus other Rhodiola species. Traditional use: Rhodiola rosea has been used in Scandinavian, Siberian, and Tibetan traditional medicine for centuries as an anti-fatigue, adaptogenic, and performance-enhancing herb. Viking warriors reportedly used it for strength and endurance; Soviet-era Russian military and athletes used it as a performance enhancer. Research trajectory: Rhodiola has one of the better clinical evidence bases among adaptogens, with multiple European RCTs showing improvements in cognitive performance, stress-related fatigue, and mood. Most RCTs use extracts standardised to both rosavin and salidroside — the dual-marker specification is now considered the quality standard. Commercial source: Rosavin is commercially available as a constituent of standardised Rhodiola rosea root extract (3% rosavins + 1% salidroside dual-marker standard) in dry powder and water-soluble liquid formats. See sourcing options below.

---

Evidence for Rosavin Applications

Cognitive performance and anti-fatigue: Multiple European RCTs (primarily Swedish and Russian) demonstrate Rhodiola rosea extract (standardised to 3% rosavin + 1% salidroside) significantly reduces mental fatigue, improves cognitive performance on speed-accuracy tasks, and reduces burnout symptoms in physicians, students, and stressed professionals. A systematic review confirmed consistent benefits across independent trials. Claim strength: Moderate.

Adaptogenic stress response: Rhodiola reduces cortisol AUC in response to stressors, normalises HPA axis reactivity, and reduces stress-induced cardiac dysfunction in animal models. AMPK activation, Hsp70 induction, and nitric oxide modulation are proposed adaptogenic mechanisms. Human data show reduced stress symptoms and improved mood in controlled trials. Claim strength: Moderate.

Physical endurance: Some human RCTs show improvements in VO2max, time to exhaustion, and reduced muscle damage markers with Rhodiola supplementation before exercise. Not all trials are consistent; effects on physical performance are smaller than cognitive anti-fatigue evidence. Claim strength: Moderate.

---

Dosage & Formulator Specification

Clinical dose: 200–600 mg/day Rhodiola rosea extract standardised to 3% rosavin + 1% salidroside (the dual-marker quality standard established in most RCTs). This translates to 6–18 mg/day rosavins and 2–6 mg/day salidroside. Acutely, doses of 200–400 mg are used 30–60 minutes before performance demands; for chronic adaptogenic effects, daily dosing is appropriate.

The SHR-5 extract (used in most Swedish RCTs) is the reference Rhodiola preparation standardised to 3% rosavins + 1% salidroside. Request both rosavin and salidroside content on CoA — extracts specifying only one marker do not meet the dual-marker clinical evidence standard. Herbuno’s Rhodiola Rosea Extract Powder should be specified to confirm both rosavin and salidroside content.

Rosavin is relatively water-soluble (due to disaccharide moiety). Stable in standard extract formats. Absorbed partly intact and partly after gut hydrolysis releasing cinnamyl alcohol and the sugars. No significant adverse effects at clinical doses; some mild stimulant-like effects at higher doses (insomnia if taken late in the day) warrant evening dosing precaution.

---

Frequently Asked Questions — Rosavin

Is rosavin or salidroside the primary Rhodiola active?
Both are considered primary actives and their combined dual-marker standardisation (3% rosavin + 1% salidroside) is the RCT-validated quality standard. Mechanistically, salidroside has stronger serotonin/dopamine reuptake inhibiting and MAO-inhibiting activity; rosavin has stronger adaptogenic and AMPK-activating properties. Extracts specifying only one marker are mechanistically incomplete relative to the clinical evidence base.

How does Rhodiola compare to ashwagandha as an adaptogen?
Rhodiola is stimulating (improves energy and alertness, may cause insomnia if taken late) while ashwagandha is calming (reduces cortisol, improves sleep, reduces anxious arousal). Rhodiola has stronger evidence for acute cognitive performance and anti-fatigue; ashwagandha has stronger evidence for HPA axis cortisol reduction and sleep quality improvement. Co-formulation provides complementary adaptogenic coverage addressing both energising and calming stress-response dimensions.

Is there a risk of Rhodiola adulteration with other Rhodiola species?
Yes — this is a documented quality concern. Other Rhodiola species (R. crenulata, R. imbricata) contain salidroside but lack rosavins. Rosavin presence is chemically diagnostic for R. rosea specifically. An extract containing only salidroside (without rosavins) indicates adulteration or substitution with a non-rosea species. Dual-marker specification (rosavins present) is therefore a botanical authenticity requirement, not just a potency specification.

Can Rhodiola cause interactions with antidepressant medications?
Rhodiola has mild MAO-inhibiting and serotonin/dopamine reuptake-inhibiting activity. At supplement doses, clinical serotonin syndrome risk with SSRIs or MAOIs is theoretical and not well-documented. Nonetheless, standard advisory language for individuals on antidepressant medications is appropriate, as with other serotonergically active botanicals.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery